The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial
Open accessAbstract
Purpose: Gemcitabine (Gem) is the standard treatment for advanced pancreatic cancer. Given the promising phase II results obtained with the Gem-oxaliplatin (GemOx) combination, we conducted a phase III study comparing GemOx with Gem alone in advanced pancreatic cancer. Patients and Methods: Patients with advanced pancreatic cancer were stratified according to center, performance status, and type of disease (locally advanced v metastatic) and randomly assigned to either GemOx (gemcitabine 1 g/m 2 as a 100-minute infusion on day 1 and oxaliplatin 100 mg/m 2 as a 2-hour infusion on day 2 every 2 weeks) or Gem (gemcitabine 1 g/m 2 as a weekly 30-minute infusion). Results: Three hundred twenty-six patients were enrolled; 313 were eligible, and 157 and 156 were allocated to the GemOx and Gem arms, respectively. GemOx was superior to Gem in terms of response rate (26.8% v 17.3%, respectively; P = .04), progression-free survival (5.8 v 3.7 months, respectively; P = .04), and clinical benefit (38.2% v 26.9%, respectively; P = .03). Median overall survival (OS) for GemOx and Gem was 9.0 and 7.1 months, respectively (P = .13). GemOx was well tolerated overall, although a higher incidence of National Cancer Institute Common Toxicity Criteria grade 3 and 4 toxicity per patient was observed for platelets (14.0% for GemOx v 3.2% for Gem), vomiting (8.9% for GemOx v 3.2% for Gem), and neurosensory symptoms (19.1% for GemOx v 0% for Gem). Conclusion: These results confirm the efficacy and safety of GemOx, but this study failed to demonstrate a statistically significant advantage in terms of OS compared with Gem. Because GemOx is the first combined treatment to be superior to Gem alone in terms of clinical benefit, this promising regimen deserves further development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Self-citationTrends in the Aggressiveness of Cancer Care Near the End of Life
Earle, C. C., Neville, B. A., Landrum, M. B., Ayanian, J. Z., Block, S. D., & Weeks, J. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.136 · Cited by 987
Van Cutsem, E., van de Velde, H., Karasek, P., Oettle, H., Vervenne, W. L., Szawlowski, A., Schoffski, P., Post, S., Verslype, C., Neumann, H., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.112 · Cited by 786
Berlin, J. D., Catalano, P., Thomas, J. P., Kugler, J. W., Haller, D. G., & Benson, A. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.149 · Cited by 729
Urdaneta, A. B. (1972) · PubMed · Cited by 632
Rocha Lima, C. M., Green, M. R., Rotche, R., Miller, W. H., Jeffrey, G. M., Cisar, L. A., Morganti, A., Orlando, N., Gruia, G., & Miller, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.082 · Cited by 588
Bramhall, S. R., Schulz, J., Nemunaitis, J., Brown, P. D., Baillet, M., & Buckels, J. A. C. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600446 · Cited by 557
Tempero, M., Plunkett, W., Ruiz van Haperen, V., Hainsworth, J., Hochster, H., Lenzi, R., & Abbruzzese, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.140 · Cited by 519
Xiong, H. Q., Rosenberg, A., LoBuglio, A., Schmidt, W., Wolff, R. A., Deutsch, J., Needle, M., & Abbruzzese, J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.040 · Cited by 479
Cited by
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Self-citationMoore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8429 · Cited by 1,926
Gillen, S., Schuster, T., Meyer zum Büschenfelde, C., Friess, H., & Kleeff, J. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000267 · Cited by 1,552
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Tempero, M. A., Malafa, M. P., Al-Hawary, M., Behrman, S. W., Benson, A. B., Cardin, D. B., Chiorean, E. G., Chung, V., Czito, B., Del Chiaro, M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0017 · Cited by 1,304
Recent progress in pancreatic cancer
Wolfgang, C. L., Herman, J. M., Laheru, D. A., Klein, A. P., Erdek, M. A., Fishman, E. K., & Hruban, R. H. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21190 · Cited by 910
Kindler, H. L., Niedzwiecki, D., Hollis, D., Sutherland, S., Schrag, D., Hurwitz, H., Innocenti, F., Mulcahy, M. F., O'Reilly, E., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 845
Advanced pancreatic carcinoma: current treatment and future challenges
Stathis, A., & Moore, M. J. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.236 · Cited by 790
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Stromal biology and therapy in pancreatic cancer
Neesse, A., Michl, P., Frese, K. K., Feig, C., Cook, N., Jacobetz, M. A., Lolkema, M. P., Buchholz, M., Olive, K. P., Gress, T. M., et al. (2011) · Gut · doi:10.1136/gut.2010.226092 · Cited by 757
Heinemann, V., Quietzsch, D., Gieseler, F., Gonnermann, M., Schönekäs, H., Rost, A., Neuhaus, H., Haag, C., Clemens, M., Heinrich, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1490 · Cited by 683
Van Cutsem, E., Vervenne, W. L., Bennouna, J., Humblet, Y., Gill, S., Van Laethem, J.-L., Verslype, C., Scheithauer, W., Shang, A., Cosaert, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0238 · Cited by 650
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
Adamska, A., Domenichini, A., & Falasca, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071338 · Cited by 610
Herrmann, R., Bodoky, G., Ruhstaller, T., Glimelius, B., Bajetta, E., Schüller, J., Saletti, P., Bauer, J., Figer, A., Pestalozzi, B., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0886 · Cited by 595
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.012 · Cited by 568
Stromal biology and therapy in pancreatic cancer: a changing paradigm
Neesse, A., Algül, H., Tuveson, D. A., & Gress, T. M. (2015) · Gut · doi:10.1136/gutjnl-2015-309304 · Cited by 559
Huguet, F., André, T., Hammel, P., Artru, P., Balosso, J., Selle, F., Deniaud-Alexandre, E., Ruszniewski, P., Touboul, E., Labianca, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.5663 · Cited by 529
Self-citationAddressing the challenges of pancreatic cancer: Future directions for improving outcomes
Hidalgo, M., Cascinu, S., Kleeff, J., Labianca, R., Löhr, J.-M., Neoptolemos, J., Real, F. X., Van Laethem, J.-L., & Heinemann, V. (2015) · Pancreatology · doi:10.1016/j.pan.2014.10.001 · Cited by 509
Self-citationPhase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
Kindler, H. L., Friberg, G., Singh, D. A., Locker, G., Nattam, S., Kozloff, M., Taber, D. A., Karrison, T., Dachman, A., Stadler, W. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.9661 · Cited by 460
Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer
Sultana, A., Smith, C. T., Cunningham, D., Starling, N., Neoptolemos, J. P., & Ghaneh, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2551 · Cited by 442
Poplin, E., Feng, Y., Berlin, J., Rothenberg, M. L., Hochster, H., Mitchell, E., Alberts, S., O'Dwyer, P., Haller, D., Catalano, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9007 · Cited by 438
Heinemann, V., Boeck, S., Hinke, A., Labianca, R., & Louvet, C. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-82 · Cited by 434
Self-citationZhu, A. X., Blaszkowsky, L. S., Ryan, D. P., Clark, J. W., Muzikansky, A., Horgan, K., Sheehan, S., Hale, K. E., Enzinger, P. C., Bhargava, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9130 · Cited by 388
Mukherjee, S., Hurt, C. N., Bridgewater, J., Falk, S., Cummins, S., Wasan, H., Crosby, T., Jephcott, C., Roy, R., Radhakrishna, G., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70021-4 · Cited by 355
Laheru, D., Lutz, E., Burke, J., Biedrzycki, B., Solt, S., Onners, B., Tartakovsky, I., Nemunaitis, J., Le, D., Sugar, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0371 · Cited by 346
Pancreatic cancer: why is it so hard to treat?
Oberstein, P. E., & Olive, K. P. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13478680 · Cited by 340
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Sohal, D. P. S., Mangu, P. B., Khorana, A. A., Shah, M. A., Philip, P. A., O’Reilly, E. M., Uronis, H. E., Ramanathan, R. K., Crane, C. H., Engebretson, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1412 · Cited by 332
Colucci, G., Labianca, R., Di Costanzo, F., Gebbia, V., Cartenì, G., Massidda, B., Dapretto, E., Manzione, L., Piazza, E., Sannicolò, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4433 · Cited by 304
Self-citationOral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer
Wolpin, B. M., Hezel, A. F., Abrams, T., Blaszkowsky, L. S., Meyerhardt, J. A., Chan, J. A., Enzinger, P. C., Allen, B., Clark, J. W., Ryan, D. P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9514 · Cited by 297
Therapeutic Advances in Pancreatic Cancer
Paulson, A. S., Tran Cao, H. S., Tempero, M. A., & Lowy, A. M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.078 · Cited by 290
Crane, C. H., Varadhachary, G. R., Yordy, J. S., Staerkel, G. A., Javle, M. M., Safran, H., Haque, W., Hobbs, B. D., Krishnan, S., Fleming, J. B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8038 · Cited by 288
Abou-Alfa, G. K., Letourneau, R., Harker, G., Modiano, M., Hurwitz, H., Tchekmedyian, N. S., Feit, K., Ackerman, J., De Jager, R. L., Eckhardt, S. G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0201 · Cited by 282
Ruzzo, A., Graziano, F., Loupakis, F., Rulli, E., Canestrari, E., Santini, D., Catalano, V., Ficarelli, R., Maltese, P., Bisonni, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1844 · Cited by 266
Albumin-bound paclitaxel in solid tumors: clinical development and future directions
Kundranda, M., & Niu, J. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s88023 · Cited by 255
Screening for Pancreatic Cancer: Why, How, and Who?
Poruk, K. E., Firpo, M. A., Adler, D. G., & Mulvihill, S. J. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31825ffbfb · Cited by 249
Current and Emerging Therapies in Metastatic Pancreatic Cancer
Manji, G. A., Olive, K. P., Saenger, Y. M., & Oberstein, P. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2319 · Cited by 145
Richards, D. A., Boehm, K. A., Waterhouse, D. M., Wagener, D. J., Krishnamurthi, S. S., Rosemurgy, A., Grove, W., Macdonald, K., Gulyas, S., Clark, M., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl081 · Cited by 101
“Some of the drugs studied to date include 5-FU, irinotecan, cisplatin, exatecan, pemetrexed and oxaliplatin [22–27].”
BackgroundRahib, L., Fleshman, J. M., Matrisian, L. M., & Berlin, J. D. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0585 · Cited by 73
Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer
Lei, F., Xi, X., Batra, S. K., & Bronich, T. K. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.255786 · Cited by 51
Schultheis, B., Strumberg, D., Bergmann, L., Graeven, U., Hanauske, A.-R., Lipp, R., Schuette, J., Saito, K., Scigalla, P., & Scheulen, M. E. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9665-x · Cited by 14
“[5, 6], 5-FU [7], capecitabine [8, 9], irinotecan [10, 11] and pemetrexed [12].”
BackgroundThota, R., Maitra, A., & Berlin, J. D. (2017) · Pancreas · doi:10.1097/mpa.0000000000000753 · Cited by 12
Metadata
- Authors
- Louvet, C., Labianca, R., Hammel, P., Lledo, G., Zampino, M. G., André, T., Zaniboni, A., Ducreux, M., Aitini, E., Taïeb, J., Faroux, R., Lepere, C., & de Gramont, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-05-20
- Volume
- 23
- Issue
- 15
- Pages
- 3509-3516
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2097642908
- Cited by
- 950
- References
- 22
- FWCI
- 28.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.